Neuphoria Therapeutics Inc. (NEUP) stock

NEUPNasdaqPharmaceutical PreparationsFiscal year ends June 30

Financials through Q4 FY2026, quarter ended Jun 30, 2026Last filing: 10-K on Sep 18, 2026Score 5/30

$2.55−0.03 (-1.16%)

Close on Nov 13, 2026Market cap $76.66KP/E –Yield –

Neuphoria Therapeutics total debt

Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.

Neuphoria Therapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

Parsed from the XBRL in Neuphoria Therapeutics's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-2160 reverse split on Feb 14, 2025
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is NEUP.

Revenue growth-92.5% · median -46.7%

Operating margin-1401.1% · median -2843.5%

Net margin-1145.7% · median -1836.7%

Advertisement
300 × 250

See a number that looks wrong?